PUBLISHER: TechNavio | PRODUCT CODE: 2172597
PUBLISHER: TechNavio | PRODUCT CODE: 2172597
Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2026-2030
The global diffuse large b-cell lymphoma (DLBCL) therapeutics market is forecasted to grow by USD 2771.2 mn during 2025-2030, accelerating at a CAGR of 8.5% during the forecast period. The report on the global diffuse large b-cell lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by aging global demographic and rising incidence, regulatory acceleration for next-generation biologics, commercialization of chemotherapy-free combination regimens.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 7.9% |
| CAGR | 8.5% |
| Incremental Value | $2771.2 mn |
Technavio's global diffuse large b-cell lymphoma (DLBCL) therapeutics market is segmented as below:
By Product
- Small molecules
- Biologics
By Application
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Others
By Therapy
- Chemotherapy
- Immunotherapy
- Combination therapies
- Others
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the dominance of off-the-shelf bispecific antibodies as one of the prime reasons driving the global diffuse large b-cell lymphoma (DLBCL) therapeutics market growth during the next few years. Also, frontline paradigm shift via targeted conjugates and integration of minimal residual disease monitoring will lead to sizable demand in the market.
The report on the global diffuse large b-cell lymphoma (DLBCL) therapeutics market covers the following areas:
- Global diffuse large b-cell lymphoma (DLBCL) therapeutics market sizing
- Global diffuse large b-cell lymphoma (DLBCL) therapeutics market forecast
- Global diffuse large b-cell lymphoma (DLBCL) therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global diffuse large b-cell lymphoma (DLBCL) therapeutics market vendors that include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Ascentage Pharma Group Intl., AstraZeneca Plc, Be One Medicines AG, Bristol Myers Squibb Co., CStone Pharmaceuticals, Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Genmab AS, Gilead Sciences Inc., Incyte Corp., Innovent Biologics Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Shanghai Henlius Biotech Inc., Takeda Pharmaceutical Ltd., Xencor Inc.. Also, the global diffuse large b-cell lymphoma (DLBCL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Therapy
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2020 - 2024
- Historic Market Size - Data Table on Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2020 - 2024 ($ million)
- 5.2 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ million)
- 5.3 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.4 Therapy segment analysis 2020 - 2024
- Historic Market Size - Therapy Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global diffuse large B-cell lymphoma (DLBCL) therapeutics market
- 6.2 Impact of geopolitical conflicts on global diffuse large B-cell lymphoma (DLBCL) therapeutics market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Product
- 8.1 Market segments
- 8.2 Comparison by Product
- 8.3 Small molecules - Market size and forecast 2025-2030
- 8.4 Biologics - Market size and forecast 2025-2030
- 8.5 Market opportunity by Product
- Market opportunity by Product ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- 9.2 Comparison by Application
- 9.3 Hospital pharmacy - Market size and forecast 2025-2030
- 9.4 Retail pharmacy - Market size and forecast 2025-2030
- 9.5 Online pharmacy - Market size and forecast 2025-2030
- 9.6 Others - Market size and forecast 2025-2030
- 9.7 Market opportunity by Application
- Market opportunity by Application ($ million)
10 Market Segmentation by Therapy
- 10.1 Market segments
- 10.2 Comparison by Therapy
- 10.3 Chemotherapy - Market size and forecast 2025-2030
- 10.4 Immunotherapy - Market size and forecast 2025-2030
- 10.5 Combination therapies - Market size and forecast 2025-2030
- 10.6 Others - Market size and forecast 2025-2030
- 10.7 Market opportunity by Therapy
- Market opportunity by Therapy ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 Japan - Market size and forecast 2025-2030
- 12.5.3 India - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 Turkey - Market size and forecast 2025-2030
- 12.6.4 UAE - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 South Africa - Market size and forecast 2025-2030
- 12.6.7 Colombia - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Aging global demographic and rising incidence
- Regulatory acceleration for next-generation biologics
- Commercialization of chemotherapy-free combination regimens
- 13.2 Market challenges
- Exorbitant treatment costs and reimbursement barriers
- Severe treatment toxicity and adverse events
- Biological heterogeneity and drug resistance mechanisms
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Dominance of off-the-shelf bispecific antibodies
- Frontline paradigm shift via targeted conjugates
- Integration of minimal residual disease monitoring
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 15.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 15.7 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.8 Daiichi Sankyo Co. Ltd.
- Daiichi Sankyo Co. Ltd. - Overview
- Daiichi Sankyo Co. Ltd. - Business segments
- Daiichi Sankyo Co. Ltd. - Key news
- Daiichi Sankyo Co. Ltd. - Key offerings
- Daiichi Sankyo Co. Ltd. - Segment focus
- SWOT
- 15.9 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.10 Genmab AS
- Genmab AS - Overview
- Genmab AS - Product / Service
- Genmab AS - Key offerings
- SWOT
- 15.11 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
- 15.12 Incyte Corp.
- Incyte Corp. - Overview
- Incyte Corp. - Product / Service
- Incyte Corp. - Key news
- Incyte Corp. - Key offerings
- SWOT
- 15.13 Innovent Biologics Inc.
- Innovent Biologics Inc. - Overview
- Innovent Biologics Inc. - Product / Service
- Innovent Biologics Inc. - Key news
- Innovent Biologics Inc. - Key offerings
- SWOT
- 15.14 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.15 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.16 Regeneron Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc. - Overview
- Regeneron Pharmaceuticals Inc. - Product / Service
- Regeneron Pharmaceuticals Inc. - Key news
- Regeneron Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.17 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 Xencor Inc.
- Xencor Inc. - Overview
- Xencor Inc. - Product / Service
- Xencor Inc. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
